-7.01%
-11.74%
-37.10%
-48.72%
-76.49%
-77.75%
-90.25%
AI Spotlight on EKSO
Company Description
Ekso Bionics Holdings, Inc.designs, develops, sells, and rents exoskeleton products in the Americas, Europe, the Middle east, Africa, the Asia Pacific, and internationally.The company operates in two segments, EksoHealth and EksoWorks.
The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods.It also provides EksoNR, a wearable bionic suit and rehabilitation device that assists physical therapists and physicians to treat patients with acquired brain injury, stroke, and spinal cord injury; and EksoUE is a wearable upper extremity assistive device that helps to reduce the effect of gravity on the wearer's shoulders and arms.
Ekso Bionics Holdings, Inc.has a license agreement with Lockheed Martin Corporation.The company was incorporated in 2005 and is headquartered in Richmond, California.
Market Data
| Last Price | 0.54 |
| Change Percentage | -7.01% |
| Open | 0.58 |
| Previous Close | 0.58 |
| Market Cap ( Millions) | 12 |
| Volume | 518528 |
| Year High | 2.32 |
| Year Low | 0.5 |
| M A 50 | 0.67 |
| M A 200 | 1.02 |
Financial Ratios
| FCF Yield | -84.90% |
| Dividend Yield | 0.00% |
| ROE | -83.09% |
| Debt / Equity | 42.68% |
| Net Debt / EBIDTA | 21.69% |
| Price To Book | 0.74 |
| Price Earnings Ratio | -0.98 |
| Price To FCF | -1.18 |
| Price To sales | 0.67 |
| EV / EBITDA | -1.1 |
News
- Nov -18 - Ekso Bionics to Showcase Its Device Technology in ‘AI for Good' Webinar on Tuesday, November 19
- Nov -12 - Ekso Bionics to Participate at the 15th Annual Craig-Hallum Alpha Select Conference
- Oct -28 - Ekso Bionics (EKSO) Reports Q3 Loss, Misses Revenue Estimates
- Oct -28 - Ekso Bionics Holdings, Inc. (EKSO) Q3 2024 Earnings Call Transcript
- Oct -28 - Ekso Bionics Announces Third Quarter 2024 Financial Results
- Oct -21 - Ekso Bionics to Report Third Quarter 2024 Financial Results on October 28, 2024
- Aug -30 - Ekso Bionics Announces Pricing of $6.0 Million Underwritten Public Offering
- Aug -26 - Ekso Bionics (EKSO) Addressable Market to Grow on CMS Update
- Jul -30 - Why Is Ekso Bionics (EKSO) Stock Down 15% Today?
- Jul -30 - Ekso Bionics Holdings, Inc. (EKSO) Q2 2024 Earnings Call Transcript
- Jul -29 - Ekso Bionics (EKSO) Reports Q2 Loss, Lags Revenue Estimates
- Jul -29 - Ekso Bionics Reports Record Quarterly Sales of $5.0 Million in Second Quarter 2024
- Jul -22 - Ekso Bionics to Report Second Quarter 2024 Financial Results on July 29, 2024
- Jun -26 - Ekso Bionics' (EKSO) New Partnership to Aid Its Ekso Devices
- Jun -17 - Ekso Bionics Appoints Deborah Lafer Scher to its Board of Directors
- Jun -10 - All You Need to Know About Ekso Bionics (EKSO) Rating Upgrade to Buy
- Jun -07 - Artificial Intelligence in the Global Prosthetic Market 2024-2033, with Profiles of Ossur, Blatchford, Ottobock, Ekso Bionics, Open Bionics, Advanced Arm Dynamics and BrainRobotics
- May -10 - Ekso Indego Personal to be Featured on ‘Health Uncensored' with Dr. Drew Pinsky
- Apr -29 - Ekso Bionics Holdings, Inc. (EKSO) Q1 2024 Earnings Call Transcript
- Apr -29 - Ekso Bionics Announces First Quarter 2024 Financial Results
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> EksoHealth
Expected Growth : 14.07 %
What the company do ?
EksoHealth is a digital health platform from Ekso Bionics Holdings, Inc. that provides data-driven insights and analytics for physical therapy and rehabilitation.
Why we expect these perspectives ?
EksoHealth's 14.07% growth driven by increasing adoption of EksoGT exoskeletons in rehabilitation centers, expansion into new markets, and growing demand for robotic solutions in healthcare. Strong sales pipeline, strategic partnerships, and investments in product development also contribute to growth.
Segment n°2 -> EksoWorks
Expected Growth : 11.7 %
What the company do ?
EksoWorks is a software platform from Ekso Bionics Holdings, Inc. that provides a suite of tools for industrial workforce augmentation and efficiency.
Why we expect these perspectives ?
EksoWorks' 11.7% growth is driven by increasing adoption of Ekso Bionics' exoskeletons in industrial and construction settings, improving worker safety and productivity. Growing demand for ergonomic solutions, expansion into new markets, and strategic partnerships also contribute to the segment's growth.
Ekso Bionics Holdings, Inc. Products
| Product Range | What is it ? |
|---|---|
| EksoGT | EksoGT is a wearable exoskeleton designed for rehabilitation of stroke and spinal cord injury patients. |
| EksoNRG | EksoNRG is a wearable exoskeleton designed for rehabilitation of patients with neurological injuries or disorders. |
| EksoUE | EksoUE is an upper body exoskeleton designed for rehabilitation of patients with upper limb impairments. |
| EksoWorks | EksoWorks is an industrial exoskeleton designed to enhance worker productivity and reduce fatigue. |
Ekso Bionics Holdings, Inc.'s Porter Forces
Threat Of Substitutes
Ekso Bionics Holdings, Inc. operates in a niche market with limited substitutes, but the threat of substitutes is still present due to the ongoing development of new technologies.
Bargaining Power Of Customers
Ekso Bionics Holdings, Inc. has a diverse customer base, which reduces the bargaining power of individual customers. Additionally, the company's products are highly specialized, making it difficult for customers to switch to alternative suppliers.
Bargaining Power Of Suppliers
Ekso Bionics Holdings, Inc. relies on a limited number of suppliers for its components and materials. While the company has some bargaining power due to its size, suppliers still have some leverage due to the specialized nature of the components.
Threat Of New Entrants
The barriers to entry in the exoskeleton market are relatively high due to the need for significant investments in research and development, as well as regulatory approvals. This limits the threat of new entrants.
Intensity Of Rivalry
The exoskeleton market is highly competitive, with several established players competing for market share. Ekso Bionics Holdings, Inc. faces intense competition from companies such as ReWalk Robotics and Hocoma AG.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 33.83% |
| Debt Cost | 4.21% |
| Equity Weight | 66.17% |
| Equity Cost | 12.14% |
| WACC | 9.46% |
| Leverage | 51.13% |
Ekso Bionics Holdings, Inc. : Quality Control
Ekso Bionics Holdings, Inc. passed 5 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| ANGO | AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use … |
| RVP | Retractable Technologies, Inc. designs, develops, manufactures, and markets safety syringes and other safety medical products for the healthcare profession in the United States, rest of North and South America, and … |
| STAA | STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The … |
| STXS | Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the … |
| BLFS | BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Retractable Technologies
A-Score
1-Year Total Return ->
🥈
BioLife Solutions
A-Score
1-Year Total Return ->
🥉
STAAR Surgical
A-Score
1-Year Total Return ->
4
Stereotaxis
A-Score
1-Year Total Return ->
5
AngioDynamics
A-Score
1-Year Total Return ->
6
